WORCESTER, Mass., and TORONTO, April 5, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced it has launched its redesigned corporate website consistent with new management's drive to establish a focused and transparent approach to the development and approval of the Company's pipeline of diabetes and immunotherapeutic vaccine products.
Aside from a new look, the Company's website will continue to evolve, providing improved descriptions of products, technologies, scientific research in progress, trial results, and new corporate relationships as they unfold. As management's strategic development plan for the Company is refined in the coming weeks and months, information will be highlighted on the website to keep stockholders fully informed as the June 8, 2011 Annual Meeting of the Generex stockholders approaches.
Investors will be able to review corporate performance information and view responses to questions from Generex's senior management. Future plans also include enrichment of Generex's social media presence on Twitter (http://twitter.com/GenerexBiotech), Facebook (http://www.facebook.com/GenerexBiotechnology) and related social media sites.
The Company has two additional website properties that are of interest: Antigen Express, Inc.'s (Generex's wholly-owned subsidiary) website (www.antigenexpress.com), and an information site that provides reference information to individuals and Healthcare Professionals who are involved, or wish to be involved, with the use of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, un
|SOURCE Generex Biotechnology Corporation|
Copyright©2010 PR Newswire.
All rights reserved